Midostaurin Approved by FDA for Acute Myeloid Leukemia

The FDA has approved midostaurin for patients with newly diagnosed acute myeloid leukemia (AML) with mutations in the FLT3 gene. The approval also covers several rare conditions.

Cancer Currents: An NCI Cancer Research Blog